NCT05029531View on ClinicalTrials.gov

Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)

PHASE3RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 23, 2021

Primary Completion Date

July 1, 2029

Study Completion Date

July 1, 2030

Conditions
Acute Lymphoblastic Leukemia, PediatricALL, Infants
Interventions
COMBINATION_PRODUCT

the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.

two-stage stratification into risk groups: Initially and According to the results of induction therapy MRD-positive patients receive a course of blinatumomab and HSCT.

Trial Locations (1)

11198

RECRUITING

Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, Moscow

All Listed Sponsors
lead

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

OTHER